• About
  • Product Pipeline
  • Investors
  • Partners
  • Medical Affairs
  • Careers
  • Contact
  • News

    • Xenon announces launch of XEN1101 Phase 3 Program

    Read News

    XEN1101, A DIFFENTIATED KV7 POTASSIUM CHANNEL OPENER

    The X-TOLE2 clinical trial now underway to examine XEN1101 administered as an adjunctive treatment for adult patients with focal onset seizures

    Download Brochure

    XEN1101-RELATED CONFERENCE POSTERS

    French et al. "XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2B Study (X-TOLE) in Adults With Focal Epilepsy"

    French et al. (Encore) "Phase 2b Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Onset Seizures (X-TOLE)"

    Kenney et al. "Rapid Onset of Efficacy of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: Results From a Phase 2b Study (X-TOLE)"

    Leung et al. "The Impact of Disease Severity on Efficacy From a Phase 2b Study of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)"

    "Design of X-TOLE2 and X-TOLE3: Two Parallel, Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies to Evaluate the Safety and Efficacy of XEN1101 as Adjunctive Therapy in the Treatment of Focal Onset Epilepsy"

    "X-ACKT: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures"

    CONNECT WITH US AT AES 2022 IN NASHVILLE

    We hope you can visit our scientific exhibit taking place on Sunday, Dec. 4th from 2-5 pm in Room 207 C on Level 2 of the Music City Center. Or, stop by Xenon's booth #1028 to learn more about our novel product pipeline.

    FOR MORE INFORMATION

    Let us know if you would like to learn more about Xenon's XEN1101 Phase 3 program, including our X-TOLE2, X-TOLE3, and X-ACKT clinical trials, by emailing us at medicalaffairs@xenon-pharma.com.